United Therapeutics Unveils Key Data on PAH and IPF Treatments at Major Medical Congresses — United Therapeutics Corporation

Event summary

United Therapeutics presented 8 data sets at ESC 2026 and ERS 2026, including late-breaking analyses from phase 3 studies on ralinepag and treprostinil.
Key findings include improved outcomes in PAH patients with connective tissue disease and early high-dose treprostinil reducing mean pulmonary arterial pressure.
The company submitted NDAs for ralinepag (PAH) and nebulized treprostinil (IPF) to the FDA in June 2026, though both remain investigational.
Presentations covered both established and investigational therapies across PAH, PH-ILD, and IPF patient populations.

The big picture

United Therapeutics is advancing its pipeline in pulmonary vascular diseases at a time when the FDA is increasingly scrutinizing rare disease therapies. The company's focus on generating evidence across multiple indications could position it as a leader in PAH and IPF treatments, though it must navigate competitive pressures and regulatory hurdles. The scale of these medical congresses provides a high-profile platform to differentiate its science from peers.

What we're watching

Regulatory Timelines: Whether the FDA will approve ralinepag and nebulized treprostinil within expected timeframes given the positive phase 3 data.
Market Differentiation: How United Therapeutics positions these therapies against competitors in the growing PAH and IPF treatment markets.
Clinical Adoption: The pace at which these data will translate into prescribing patterns among pulmonologists and cardiologists.